Sentences with phrase «aids vaccine research»

USAID's investments have been put to work by IAVI to enable both AIDS vaccine research and the cultivation of scientific and technical capacity at clinical research centers in developing countries that conduct vaccine trials in partnership with the organization.

It raises the expectation that if only enough money were thrown into AIDS vaccine research, then a solution would appear in the not too distant future.

AIDS Vaccine is the largest and most prestigious global scientific conference focused exclusively on AIDS vaccine research.

These workshops have presented an important opportunity to bring together scientists who are contributing actively to topics such as aquaculture, farmed animal biotechnology, biodiversity, plant genome research, cellular microbiology, and AIDS vaccine research and diagnostics.

Not exact matches

Developing a vaccine against HIV is still our best hope for containing the AIDS pandemic, says Danilo Casimiro, Merck's director of basic vaccine research.

AIDS research today suffers a lot from our inability to figure out a route to make a vaccine.

Scientists led by Hunter at Emory Vaccine Center / Center for AIDS Research teamed up with lead author Jonathan Carlson, PhD, and colleagues at Microsoft Research.

Contributing to work on smallpox, polio, and vaccine development, primates allow research on potential treatments for hepatitis C and B, Ebola and Marburg viruses, and HIV / AIDS.

We are hopeful that this research takes us one step closer to developing an AIDS vaccine.»

The team was led by Barton Haynes, M.D., director of the Duke Center for HIV / AIDS Vaccine Immunology - Immunogen Discovery (CHAVI - ID) and the Duke Human Vaccine Institute, and John Mascola, M.D., director of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Thirty years of struggle and research have led to dozens of treatments for HIV / AIDS — although both a cure and an effective vaccine remain elusive

«We've shown that a specific type of these cells, known as follicular helper T (Tfh) cells are not only necessary, but are a limiting factor that differentiates between an average and a potent antibody response to HIV,» says Crotty, a scientific collaborator with the Center for HIV / AIDS Vaccine Immunology & Immunogen Discovery (CHAVI - ID), a major research consortium led by The Scripps Research Inresearch consortium led by The Scripps Research InResearch Institute.

The move has outraged the broader community because the U.S. Military HIV Research Program plays a unique role in AIDS vaccine development.

Dr. Michael currently serves various NIH committees dealing with AIDS research and vaccines.

The results came as a surprise to HIV - vaccine skeptics in the AIDS (acquired immunodeficiency syndrome) research field, whose numbers have increased after years of failed vaccine trials.

HeLa cell - based research has been instrumental in developing vaccines and fighting AIDS and cancer, but it has not been without controversy.

The Gates Foundation brings treatment to the indigent and funds lifesaving research, including development of new tuberculosis, malaria, and AIDS vaccines.

«We have learned in that period of time how formidable an adversary HIV is,» says immunologist Wayne Koff, senior vice president for research and development at the International AIDS Vaccine Initiative (IAVI).

Global spending for HIV vaccine research increased from $ 186 million in 1997 to $ 759 million in 2005, according to the Joint United Nations Program on HIV / AIDS.

The work and other similar, recent studies could also help «redefine» how vaccines are developed to make them more effective and less likely to have side effects, says Wayne Koff, the chief scientific officer at the International AIDS Vaccine Initiative in New York City, who was not involved with the research.

At present the MRC's AIDS research is divided into two arms: the strategic programme, which covers work on the nature of AIDS and its treatment, and monitors the spread of HIV; and the directed programme, which is targeted specifically at developing drugs and vaccines.

But despite 2 decades of research, several potential AIDS vaccines have failed to teach the immune system to produce antibodies that can stop HIV.

International AIDS Vaccine Initiative, Neutralizing Antibody Center, and Collaboration for AIDS Vaccine Discovery, Scripps Research Institute, La Jolla, CA 92037, USA.

Funding: This work was supported by the European Commission sixth Frame Work Programme as part of the European Vaccines and Microbicides Enterprise (EUROPRISE), the European Commission seventh Frame Work Programme as part of the Combined Highly Active Anti-retroviral Microbicides project (CHAARM)[to RAW], the Bill and Melinda Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD grant 38637 [to RAW] and grant 1032144 [to MSS]-RRB-, and the UK Medical Research Council [RAW and AF].

Led by scientists at the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI), the results offer important insight into a potential AIDS vaccine Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI), the results offer important insight into a potential AIDS vaccine vaccine design.

We carry out translational research programmes to develop infectious disease vaccines, therapeutics and diagnostics using animal models of tuberculosis, influenza, HIV / AIDS, Clostridium difficile, meningococcal disease, chlamydia, burkholderia and anthrax, as well as emerging viral diseases such as Crimean Congo haemorrhagic fever.

William Schief is a Professor in the Immunology and Microbial Science Department at The Scripps Research Institute in La Jolla, CA, Director for Vaccine Design at the International AIDS Vaccine Initiative (IAVI), and an Associate Member of the Ragon Institute of MGH, MIT and Harvard.

Two presentations on Emory research at last week's AIDS Vaccine 2010 conference concerned adjuvants.

Dr. Pontiano Kaleebu, Chairman Africa AIDS Vaccine Program and Acting Director of Uganda Virus Research Institute, delivered a strong keynote address that reiterated the importance of an HIV vaccine, what it will take to develop an effective vaccine and how community members can help with the international Vaccine Program and Acting Director of Uganda Virus Research Institute, delivered a strong keynote address that reiterated the importance of an HIV vaccine, what it will take to develop an effective vaccine and how community members can help with the international vaccine, what it will take to develop an effective vaccine and how community members can help with the international vaccine and how community members can help with the international effort.

«The two greatest challenges remaining in HIV / AIDS research are finding a cure and developing a safe and effective preventive vaccine,» said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, which is leading the vaccine trial.

Ertl's research centers on developing vaccines for an array of diseases and conditions — including AIDS and some forms of cancer — not typically considered to be treated using this approach.

Funding: NIH's National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and National Center for Research Resources (NCRR); the Bill and Melinda Gates Foundation; and the International AIDS Vaccine Initiative and its donors, including the U.S. Agency for International Development (USAID).

Ernestine Mefor Halle University of Yaounde II / Cameroon Virus Research Institute / International AIDS Vaccine Initiative / HIV Vaccine Program,, Cameroon

Research Focus: Since 2008, I have been working as a Scientific Curator for the IEDB project, a globally - utilized bioinformatics research tool to aid development of vaccines, immunotherapeutics, and diagResearch Focus: Since 2008, I have been working as a Scientific Curator for the IEDB project, a globally - utilized bioinformatics research tool to aid development of vaccines, immunotherapeutics, and diagresearch tool to aid development of vaccines, immunotherapeutics, and diagnostics.

It is also acknowledges the vital contributions of approximately 20,000 volunteers enrolled in AIDS vaccine trials around the world today who have selflessly committed to advancing research.

For example, the UK government's program for tackling HIV and AIDS in the developing world, which was published shortly after the Bangkok meeting, makes the unqualified comment that the enterprise «will accelerate research and development of an effective vaccine.»

After twenty - three years of intense research into the human immunodeficiency virus (HIV), together with the accumulated experience of more than twenty million deaths from the in - fection worldwide, there is still no prospect of a vaccine to prevent AIDS.

MHRP is dedicated to bringing about an AIDS - free future through cutting - edge research aimed at developing a globally effective HIV vaccine and discovering therapies that can lead to long - term HIV remission.

National Institute of Allergy and Infectious Diseases (NIAID) NIAID is the primary agency of the US government devoted to research on HIV / AIDS and the sponsor of the HIV Vaccine Trials Network.

At the Bangkok AIDS conference held in July of this year, Seth Berkley, IAVI's president, argued that «only a vaccine can end the epidemic,» that «a vaccine is achievable,» and that spending on vaccine research must double to $ 1.3 billion annually in order to find it.

Research on HIV over the past decade has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very...

Among other things, it features articles on new developments in HIV cure research, recent studies that show promise but also possible pitfalls of using adenovirus vectors in HIV vaccine candidates, and the funding crisis at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

A team led by scientists at The Scripps Research Institute (TSRI) working with the International AIDS Vaccine Initiative (IAVI) has discovered a new vulnerable site on the HIV virus.

His researches led to the development of an AIDS vaccine, still in clinical trials.

Research & Development IAVI worked with the Japanese biotech company DNAVEC, based in Tsukuba City, to jointly develop an AIDS vaccine candidate based on its novel Sendai vector technology.